An upgrade from a reputable analyst like David Nierengarten can significantly influence investor sentiment and potentially lead to a short-term increase in stock price. The upgrade to Outperform suggests that Wedbush sees positive developments or financial performance in AnaptysBio's future, which could attract more investors to the stock.